Effect of sorafenib on serum Tg and TgAb levels in patients with radioactive iodine-refractory differentiated thyroid carcinoma
Objective To analyze the effects of sorafenib for patients with radioactive iodine-refractory differentiated thyroid cancer(RAIR-DTC).Methods Thirty RAIR-DTC patients treated in our hospital from March 2020 to March 2022 were enrolled,and they were assigned into group A(13 cases,conventional treatment)and group B(17 cases,conventional treatment+sorafenib)according to different treatment regimens.The effects on months 1,2,4,6 of treatment between groups were compared.Results On months 1,2,4,6 of treatment,significantly lower triglyceride(Tg)concentration,vascular endothelial growth factor(VEGF),telomere length(TL),and higher thyroglobulin antibody(TgAb),effect size(ES)were found in group B than those of group A(all P＜0.05).The difference was statistically significant in the incidence of adverse reactions,survival rate between groups at different time points(P＜0.05).The efficiency and the 36-item Short Form Health Survey(SF-36)score on month 6 of treatment were significantly higher in the group B than in the group A(P＜0.05).Conclusion Sorafenib can effectively reduce Tg concentration and VEGF level,increase TgAb concentration and ES level,significantly improve the quality of life in RAIR-DTC patients.It has good safety and effectiveness,and without increasing adverse reactions.
sorafenibiodine-refractory differentiated thyroid carcinomaserum Tg and TgAb levelsincidence of adverse reactions
NETL
NSTL
万方数据
